Cortisone and Covid19 (coronavirus)

A meta-analysis ("pooled" study of all available clinical trial about a topic) published in September 2020 in one of the most prestigious medical journals (JAMA) shows that cortisone given to the sickest patients with Covid-19 (hospitalized patients, with the distress respiratory syndrome) improves survival in these patients. In total, 7 clinical trials were [...]

2020-09-24T10:16:30+02:00September 24th, 2020|Tags: , , , , |

Results of the online questionnaire

Thank you for your participation. You were almost 1400 to answer the questionnaire posted on our site a few months ago. Through your participation, we can better understand of physicians' practices regarding measures associated with long-term glucocorticoid therapy. We have highlighted the very heterogeneous practices between specialists. A summary of the results is reported [...]

2019-02-13T12:38:52+01:00November 7th, 2018|

Corticosteroids and infections

Corticosteroids increase the risk of common infections It was already known that corticosteroid therapy increased the risk of some opportunistics infections such as tuberculosis or certain mycoses/parasitoses. There was less knowledge about the risk of more common infections, such as chicken pox or lower lung infections. By analyzing British data from patients exposed to [...]

2019-02-12T16:51:14+01:00August 2nd, 2017|

Use of systemic corticosteroids in France

Are systemic corticosteroids frequently prescribed? No data were available on the frequency of use of corticosteroids in France. Using national data from health insurance, a team of French researchers was interested in the oral prescriptions of corticosteroids in France during the period 2007-2014. It was found that about 15% of French subjects were prescribed [...]

2019-02-12T16:50:29+01:00August 2nd, 2017|

Oral or intraveinous corticosteroids for the treatment of multiple sclerosis

Oral corticosteroids could be as efficient as intraveinous corticosteroids for the treatment of multiple sclerosis relapses High doses of intravenous methylprednisolone are recommended to treat relapses in patients with multiple sclerosis, but can be inconvenient and expensive. This study aimed to assess whether oral administration of high-dose methylprednisolone was non-inferior to intravenous administration. This [...]

2019-02-12T16:49:52+01:00February 24th, 2016|

Budesonide for Crohn disease

Efficacy and tolerance of budesonide for the treatment of Crohn disease Corticosteroids are commonly used for the induction of remission in Crohn's disease. However, traditional corticosteroids can cause significant adverse events. Budesonide is an alternative glucocorticoid with limited systemic bioavailability. One of the aims of this study was to evaluate the efficacy and safety [...]

2019-02-12T16:49:11+01:00February 24th, 2016|

Corticosteroids and sciatica

Limited impact of corticosteroid therapy on sciatica due to a herniated disk Oral steroids are commonly used to treat acute sciatica due to a herniated disk but have not been evaluated in an appropriately powered clinical trial. The aim of this study was to determine if oral prednisone was more [...]

2019-02-12T16:48:35+01:00February 24th, 2016|

Short-term corticosteroid therapy and appetite/weight gain

Short-term corticosteroid therapies do no induce a significant increase of appetite or weight Oral corticosteroids are an efficacious treatment for asthma exacerbations, yet risk of adverse effects may decrease patient adherence to therapy. In particular, changes in appetite and dietary intake, which lead to weight gain and changes in body composition, are considered undesirable. [...]

2019-02-12T16:47:58+01:00February 24th, 2016|

Monitoring of patients on long term glucocorticoid therapy

An unsatisfactory monitoring About 1% of the general population receives long-term systemic glucocorticoids. The monitoring provided to these patients is unknown. A population-based cohort study using The Health Improvement Network database was conducted. A total of 100,944 adult patients prescribed systemic glucocorticoids for >3 months between January 2000 and December [...]

2019-02-12T16:47:22+01:00May 8th, 2015|

Corticosteroid for nephrotic syndrome in children

Efifcacy and harm The aim of this review was to assess the benefits and harms of different corticosteroid regimens in children with steroid-sensitive nephrotic syndrome (SSNS). The benefits and harms of therapy were studied in two groups of children 1) children in their initial episode of SSNS, and 2) children who experience a relapsing [...]

2019-02-12T16:46:44+01:00May 8th, 2015|
Go to Top